Because patients often prefer oral to intravenous chemotherapy, a new effective oral agent for multi-drug treatment would be useful in treating older women with breast cancer.

In one U. S. study, scientists found there were 31 percent fewercases of breast cancer among women who took Fosamax or other oralbisphosphonates than among women who didn't.